Skip to content
Silver Journal

Patients Stopping Anti-Obesity Injections Gain Back Pounds Four Times Faster Than Those on Conventional Diets

Illustration of pharmaceutical syringe and scale
Weight management involves ongoing approaches.

Fresh analysis suggests that individuals who stop using blockbuster slimming jabs like Wegovy and Mounjaro may regain shed pounds far faster than those who end traditional diet and exercise plans.

Published data in a leading health publication demonstrates that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.

"Users using these medications must be aware of the danger of fast weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.

That rate of recovery implies a return to original mass in about a year and a half.

Comparing Approaches

The analysis, which looked at 37 of trials involving thousands of participants, contrasted the results of these new drugs with conventional dieting.

The team note that people who shed pounds through lifestyle changes alone typically see a more gradual weight regain—around 0.1 kg a month—once they finish.

The Reason for the Rapid Rebound

Experts propose the mode of action of the drugs explains the accelerated rebound.

The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating far more likely."

An Ongoing Condition?

Health authorities suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.

Professionals say that, given the likelihood of relapse, the treatment should be considered long-term.

This view is reinforced by drug manufacturers, who say that the results "highlight the persistent nature of obesity," akin to managing diseases like diabetes.

Patient Experiences

People who have stopped the jabs explain a sudden resurgence of appetite.

"It felt as if a switch flipping and I was suddenly starving," described an individual.

The struggle is worsened if individuals have not established lasting dietary or behavioural modifications during therapy.

Growing Interest

Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.

  • Use is greater among females compared to males.
  • The middle-aged demographic shows the greatest usage rates.
  • A large proportion access the drugs through private prescriptions rather than the NHS.

Ultimately, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and long-term success hinges on combined behavioural management.

JW
The writer

Janice Ward

Elena is a freelance writer and content strategist who loves exploring the intersection of technology and everyday life.

Silver Journal

Type to search articles.